HOUSE BILL NO. 19
View Daily Data Tracking History
View Bill Text
View Statement of Purpose / Fiscal Impact
Text to be added within a bill has been marked with Bold and
Underline. Text to be removed has been marked with
Strikethrough and Italic. How these codes are actually displayed will
vary based on the browser software you are using.
This sentence is marked with bold and underline to show added text.
This sentence is marked with strikethrough and italic, indicating
text to be removed.
H0019........................................................by MR. SPEAKER
Requested by Board of Pharmacy
CONTROLLED SUBSTANCE ACT - Amends existing law to add carisoprodol to
Schedule IV of the Uniform Controlled Substance Act.
01/11 House intro - 1st rdg - to printing
01/11 Rpt prt - to Health/Wel
H0019
|||| LEGISLATURE OF THE STATE OF IDAHO ||||
Fifty-fifth Legislature First Regular Session - 1999
IN THE HOUSE OF REPRESENTATIVES
HOUSE BILL NO. 19
BY MR. SPEAKER
Requested by: Board of Pharmacy
1 AN ACT
2 RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT; AMENDING SECTION 37-2711,
3 IDAHO CODE, BY THE ADDITION OF CARISOPRODOL TO CONTROLLED SUBSTANCES AND
4 TO MAKE TECHNICAL CORRECTIONS.
5 Be It Enacted by the Legislature of the State of Idaho:
6 SECTION 1. That Section 37-2711, Idaho Code, be, and the same is hereby
7 amended to read as follows:
8 37-2711. SCHEDULE IV. (a) Schedule IV shall consist of the drugs and
9 other substances, by whatever official name, common or usual name, chemical
10 name, or brand name designated, listed in this section.
11 (b) Narcotic drugs. Unless specifically excepted or unless listed in
12 another schedule, any material, compound, mixture, or preparation containing
13 any of the following narcotic drugs, or their salts calculated as the free
14 anhydrous base or alkaloid, in limited quantities as set forth below:
15 (1) No more than 1 milligram of difenoxin and not less than 25 micrograms
16 of atropine sulfate per dosage unit;
17 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
18 2-diphenyl-3-methyl-2-propionoxybutane).
19 (c) Depressants. Unless specifically excepted or unless listed in another
20 schedule, any material, compound, mixture, or preparation which contains any
21 quantity of the following substances, including its salts, isomers, and salts
22 of isomers whenever the existence of such salts, isomers, and salts of isomers
23 is possible within the specific chemical designation:
24 (1) Alprazolam;
25 (2) Barbital;
26 (3) Bromazepam;
27 (4) Camazepam;
28 (5) Chloral betaine;
29 (6) Chloral hydrate;
30 (7) Chlordiazepoxide;
31 (8) Clobazam;
32 (9) Clonazepam;
33 (10) Clorazepate;
34 (11) Clotiazepam;
35 (12) Cloxazolam;
36 (13) Delorazepam;
37 (14) Diazepam;
38 (15) Estazolam;
39 (16) Ethchlorvynol;
40 (17) Ethinamate;
41 (18) Ethyl loflazepate;
42 (19) Fludiazepam;
43 (20) Flurazepam;
2
1 (21) Halazepam;
2 (22) Haloxazolam;
3 (23) Ketazolam;
4 (24) Loprazolam;
5 (25) Lorazepam;
6 (26) Lormetazepam;
7 (27) Mebutamate;
8 (28) Medazepam;
9 (29) Meprobamate;
10 (30) Methohexital;
11 (31) Methylphenobarbital (mephobarbital);
12 (32) Midazolam;
13 (33) Nimetazepam;
14 (34) Nitrazepam;
15 (35) Nordiazepam;
16 (36) Oxazepam;
17 (37) Oxazolam;
18 (38) Paraldehyde;
19 (39) Petrichloral;
20 (40) Phenobarbital;
21 (41) Pinazepam;
22 (42) Prazepam;
23 (43) Temazepam;
24 (44) Tetrazepam;
25 (45) Triazolam;
26 (46) Quazepam;
27 (47) Zolpidem.
28 (d) Fenfluramine -- Any material, compound, mixture, or preparation which
29 contains any quantity of the following substances, including its salts,
30 isomers (whether optical, position, or geometric), and salts of such isomers,
31 whenever the existence of such salts, isomers, and salts of isomers is possi-
32 ble:
33 (1) Fenfluramine.
34 (e) Stimulants. Unless specifically excepted or unless listed in another
35 schedule, any material, compound, mixture, or preparation which contains any
36 quantity of the following substances having a stimulant effect on the central
37 nervous system, including its salts, isomers (whether optical, position, or
38 geometric), and salts of such isomers whenever the existence of such salts,
39 isomers, and salts of isomers is possible within the specific chemical desig-
40 nation:
41 (1) Cathine ((+)-norpseudoephedrine);
42 (2) Diethylpropion;
43 (3) Fencamfamin;
44 (4) Fenproporex;
45 (5) Mazindol;
46 (6) Mefenorex;
47 (7) Pemoline (including organometallic complexes and chelates thereof);
48 (8) Phentermine;
49 (9) Pipradrol;
50 (10) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
51 (f) Other substances. Unless specifically excepted, or unless listed in
52 another schedule, any material, compound, mixture or preparation which con-
53 tains any quantity of the following substance s , including its their salts:
55 (1) Pentazocine ;
3
1 (2) Carisoprodol .
2 (g) The board may except by rule any compound, mixture, or preparation
3 containing any depressant substance listed in subsection (c) of this section
4 from the application of all or any part of this act if the compound, mixture,
5 or preparation contains one (1) or more active medicinal ingredi-
6 ents not having a depressant effect on the central nervous system, and if the
7 admixtures are included therein in combinations, quantity, proportion, or con-
8 centration that vitiate the potential for abuse of the substances which have a
9 depressant effect on the central nervous system.
STATEMENT OF PURPOSE
RS08347
Add to Idaho Code 37-2711 Schedule IV of the Uniform Controlled
Substance Act Chapter 27, Title 37, the drug carisoprodol. This
change is being requested because of the increased abuse of this
drug. Restricts prescriptions for this drug to five refills or six
months and will place it in the tracking system.
FISCAL IMPACT
No impact on the General Fund. No cost to the general public or
practitioners. Implementation of legislation will be from the
Board of Pharmacy dedicated funds.
CONTACT
Name: Richard Markuson
Agency: Board of Pharmacy
Phone: 334-2356
Statement of Purpose/Fiscal Impact H 1